14 completed, 11 recruiting, 8 terminated, 8 unknown. 33 Phase 2, 11 Phase 1, 10 Phase 3, 5 Not applicable.
Follow Homoharringtonine: new trials by email Literature Review of Homoharringtonine trials Research Report on Homoharringtonine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| VAH vs VA in Newly Diagnosed Elderly AML Venetoclax, Azacitidine, Homoharringtonine - Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years) | Phase 3 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 308 | 2026-04-10 | 2026-04-13 |
| Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) Intervention for Venetoclax, Intervention for Homoharringtonine, Intervention for Azacitidine - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | First People's Hospital of Hangzhou | 61 | 2026-03-31 | 2026-04-02 |
| Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients Lisafotoclax, Decitabine, Homoharringtonine - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 35 | 2026-03-01 | 2026-04-01 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study homoharringtonine, Radical prostatectomy - Prostate Cancer | Phase 2 | Recruiting | baotai Liang | 93 | 2025-04-20 | 2025-11-18 |
| Newly-diagnosed Pediatric T-cell ALL Protocol Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 610 | 2025-03-11 | 2025-08-26 |
| HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML daunorubicin, Venetoclax, cytarabine - AML | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 41 | 2025-01-21 | 2026-05-13 |
| VHAG in Treating R/R T-ALL/LBL Venetoclax, homoharringtonine, Cytarabine (Ara-C) - Acute T Lymphpblastic Leukemia/Lymphoma | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 50 | 2024-12-01 | 2024-12-19 |
| Intermediate-dose HAD Regimen for CEBPA Double-mutated AML HAD, Daunorubicin+Cytarabine - AML | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 148 | 2024-08-13 | 2026-08-10 |
| Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. Venetoclax, Azacitidine and Homoharringtonine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 56 | 2024-07-02 | 2026-03-03 |
| MRD-positive AML Clinical Study Ivosidenib, Gilteritinib, Venetoclax - AML, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 537 | 2024-05-11 | 2026-08-10 |
| Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL Homoharringtonine, venetoclax, Cytarabine - ETP-ALL | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 81 | 2024-04-03 | 2025-02-17 |
| Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia Ivosidenib, Venetoclax, Gilteritinib - AML, Refractory | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 458 | 2024-02-22 | 2026-08-07 |
| Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML Homoharringtonine, Cytarabine, Etoposide - AML, Childhood, Acute Myeloid Leukemia | Phase 2 | Recruiting | Children's Hospital of Soochow University | 500 | 2024-01-01 | 2024-08-22 |
| Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients Selinexor, Homoharringtonine, Cytarabine - Relapsed/Refractory AML | Not applicable | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2023-05-01 | 2023-05-06 |
| Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML Venetoclax, Homoharringtonine, Cytarabine - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 60 | 2023-03-01 | 2023-04-07 |
| Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Selinexor, Homoharringtonine, Daunorubicin - Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Recruiting | Shanxi Bethune Hospital | 50 | 2023-01-29 | 2024-10-22 |
| Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia cladribine + homoharringtonine + cytarabine - Acute Myeloid Leukemia, Adult | Phase 2 | Completed | First Affiliated Hospital of Zhejiang University | 65 | 2022-10-26 | 2026-02-04 |
| Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) Omacetaxine, Venetoclax - Relapsed or Refractory Hematologic Malignancies | Phase 1 | Completed | University of Illinois at Chicago | 6 | 2022-06-21 | 2026-03-16 |
Showing 20 of 50. Sign in to see all of them.
Leukemia, Myeloid, Acute (25) · Leukemia (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Leukemia, Myeloid, Chronic-Phase (7) · Recurrence (5) · Hematologic Neoplasms (3) · Myelodysplastic Syndromes (3) · Neoplasm, Residual (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1) · Congenital Abnormalities (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Monocytic, Acute (1)
Institute of Hematology & Blood Diseases Hospital, China (5) · M.D. Anderson Cancer Center (5) · First Affiliated Hospital of Zhejiang University (4) · National Cancer Institute (NCI) (4) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · The First Affiliated Hospital of Soochow University (4) · ChemGenex Pharmaceuticals (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · The University of Hong Kong (2) · University of Illinois at Chicago (2) · Air Force Military Medical University, China (1) · Alliance for Clinical Trials in Oncology (1) · Ascentage Pharma Group Inc. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Children's Hospital of Soochow University (1)
China (26) · United States (21) · France (3) · Hong Kong (3) · Canada (2) · Germany (2) · Hungary (2) · India (2) · Italy (2) · Poland (2) · Singapore (2) · United Kingdom (2) · Belgium (1) · Netherlands (1) · South Korea (1)
Jorge Cortes, MD (3) · Anskar Leung, Professor (2) · Elias Jabbour, MD (2) · John Quigley, MD (2) · Adam R Craig, M.D., PhD (1) · Andreas Hochhaus, MD Prof Dr (1) · Courtney DiNardo, MD (1) · Dan DeAngelo, MD (1) · Daniel Pollyea, MD (1) · Evelena Ontiveros (1) · Guopan Yu, PhD (1) · Hagop Kantarjian, MD (1) · Hagop M. Kantarjian, MD (1) · Han Yue, Ph.D (1)
PMID 22896000, PMID 23468307, PMID 29427994, PMID 32029439, PMID 35274287, PMID 35982483, PMID 36568250, PMID 40979071, PMID 41140451
U10CA031946 (2), N01CM17003 (1), P30CA016056 (1), P30CA016672 (1), U01CA070172 (1)